SAN DIEGO, Aug. 23, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that its wholly owned subsidiary, NexMed USA, has received clearance from the U.S. Food and Drug Administration (“FDA”) to market its second, over-the-counter (“OTC”) anti-itch drug, Hydrocortisone-D™, containing the Company’s NexACT® technology.
